This story suggested that lingering fear from the 1990s fen-phen scare continues to drive patients away from the “latest generation” of weight-loss drugs, which, it asserted, could safely help some people with obesity lose enough weight to improve their risk factors for heart disease.
But the story didn’t give readers much information to go on. There was no data quantifying the benefits of drugs now on the market or comparing them with alternatives, such as surgery. The story also didn’t mention cost or potential harms and relied largely on quotes from two physicians who have received significant compensation from companies that make weight-loss drugs–which wasn’t disclosed in the story. It is vital that journalists disclose such details.
The story made a lot of general statements about weight-loss medications but named just one that’s on the market — lorcaserin (Belviq).
Medications for obesity have side effects and can be expensive. Those factors should be mentioned in news coverage, which should also give specifics on the evidence.
Eight years ago we reviewed a WebMD story about the weight-loss drug lorcaserin, which is highlighted in this story. Much of what we wrote then seems to still apply:
Drug companies want a diet pill that works and that doesn’t kill people in the process. If they can create one that does, they will make a mountain of money. … The evidence that this drug is a big improvement, though, is shaky.
The story mentioned cost and lack of insurance coverage as factors in the low uptake of weight loss drugs, but it doesn’t give data. The drug highlighted in the story, lorcaserin, marketed in the U.S. as Belviq, costs $285 for a 30-day supply if you pay out of pocket, according to web sources. It wasn’t made clear how long people must stay on these drugs, which also affects cost.
Th story claimed the latest generation of diet pills can help “shave off enough excess fat to improve heart disease risk factors such as hypertension, high blood sugar and high cholesterol.”
Specifically, that the drug lorcaserin (Belviq) helped “nearly” 40% of patients have sustained weight loss of more than 5% of body weight, which it said “is associated with a 50 percent lower risk of diabetes and a 10 percent loss is associated with an 80 percent lower risk.”
It also said patients in a lorcaserin study “did see improvements in hypertension and blood sugar levels with weight loss.”
When we looked up the results in a large study published in the New England Journal of Medicine, the numbers aren’t as impressive sounding:
Although the story kept referring to weight loss drugs as a group, the story focused mostly on lorcaserin, including a three-year study that showed lorcaserin didn’t increase the risk of bad heart events versus a placebo in patients at high risk of heart disease. However, the story didn’t mention side effects and uncertainty about long-term use of that drug.
An accompanying editorial to the lorcaserin study said that the drug “may best be used on a cautious basis according to the needs of individual patients,” and mentioned uncertain safety of its long-term use as well as side effects such as headache, fatigue, dizziness, diarrhea, and nausea that led some patients stop using it.
Other research has raised concern about an increased risk of depression and other side effects that might outweigh lorcaserin’s benefits.
The story focused mostly on one study of lorcaserin, and did not give any other information about the evidence for other weight-loss drugs that are relatively new to the market.
The story also didn’t caution against extrapolating from weight loss to other health outcomes that may or may not be affected by the drug. Just because a pill is effective for losing weight, doesn’t necessarily mean it will also lead to reduced risk of heart attacks or diabetes (as we saw with fen-phen).
The story accurately stated that two-thirds of Americans have obesity or overweight. It could have been clearer explaining how not everyone in this group experiences health risks, and it’s not always clear why. It also could have avoided some stigmatizing language such as “packing on the pounds” and “fatter.”
The story didn’t disclose that two physician sources, Erin Bohula and Louis Aronne, received payments in the tens of thousands of dollars in connection with weight drugs, according to ProPublica’s Dollars for Docs database.
A third physician quoted in the story, Vijaya Surampudi, has received smaller payments from Novartis that were not tied to a weight-loss drugs.
The story would have benefited from more independent sources.
The story did mention diet and exercise, but did not mention weight-loss surgery and didn’t explain how weight-loss drugs stack up against other interventions.
The story makes it clear that, in general, the “latest generation” of weight loss drugs are FDA approved. But it never explains which ones fall under that category. There are at least nine weight loss drugs on the market.
The story described that the “latest generation” of weight loss drugs that can “pare away the pounds without harmful effect.” But it remains to be seen whether that’s in fact the case.
The story does not appear to rely on a news release.